Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07133659) titled 'Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Al-Mustansiriyah University
Condition:
ITP - Immune Thrombocytopenia
Intervention:
Drug: Avatrombopag 20 mg Oral Tablet
Recruitment Status: Recruiting
Phase: Phase 4
Date of First Enrollment: June 8, 2025
Target Sample Size: 25
Countries of Recruitment:
Iraq
To know more, visit https://clinica...